Omnicare (NYS: OCR) reported earnings on Feb. 23. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Dec. 31 (Q4), Omnicare beat expectations on revenues and beat slightly on earnings per share.
Compared to the prior-year quarter, revenue was unchanged and GAAP earnings per share grew.
Gross margins expanded, operating margins shrank, and net margins improved.
Omnicare tallied revenue of $1.56 billion. The nine analysts polled by S&P Capital IQ expected revenue of $1.52 billion on the same basis. GAAP reported sales were 0.1% lower than the prior-year quarter's $1.56 billion.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
Non-GAAP EPS came in at $0.58. The 10 earnings estimates compiled by S&P Capital IQ forecast $0.57 per share on the same basis. GAAP EPS were $0.28 for Q4 compared to -$0.57 per share for the prior-year quarter.
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 23.1%, 90 basis points better than the prior-year quarter. Operating margin was 6.8%, 100 basis points worse than the prior-year quarter. Net margin was 2.0%, 620 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $1.54 billion. On the bottom line, the average EPS estimate is $0.62.
Next year's average estimate for revenue is $6.19 billion. The average EPS estimate is $2.52.
The stock has a three-star rating (out of five) at Motley Fool CAPS, with 224 members out of 244 rating the stock outperform, and 20 members rating it underperform. Among 86 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 83 give Omnicare a green thumbs-up, and three give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Omnicare is outperform, with an average price target of $33.10.
The health-care investing landscape is littered with also-rans and a few major winners. Is Omnicare prepared for the future? Read "Discover the Next Rule-Breaking Multibagger" to learn about a company Fool co-founder David Gardner believes will deliver amazing returns during the next few years. Click here for instant access to this free report.
Add Omnicare to My Watchlist.
At the time thisarticle was published Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.